Advertisement
ABBV vs INSM
Which Stock Would AI Choose? AbbVie Inc. (ABBV) vs. Insmed Incorporated (INSM) Stock Comparison
Key Takeaways
- AbbVie Inc. (ABBV) offers stability with ~$400B market cap, diversified revenue exceeding $61B, and a low beta of 0.33, contrasting Insmed Incorporated (INSM)'s ~$30B cap and focus on rare lung diseases.
- ABBV shares have shown modest YTD gains around 0-1% with recent positive Phase 1 obesity data, while INSM experienced volatility, including a late-2025 study setback offset by strong Brinsupri sales.
- Recent market activity highlights ABBV's immunology growth via Skyrizi and Rinvoq amid competition, versus INSM's momentum from Brinsupri launch exceeding estimates at nearly $145M in its first full quarter.
- Analyst sentiment remains optimistic for both, with ABBV price targets up to $260 and INSM at $211, reflecting growth potential in pharma versus biotech upside.
- Relative performance favors INSM over longer horizons (86% 1-year return) but ABBV for stability in recent weeks amid sector rotations.
Introduction
AbbVie Inc. (ABBV) and Insmed Incorporated (INSM) represent contrasting profiles in the biopharmaceutical sector: a large-cap diversified leader versus a mid-cap rare disease specialist. This stock comparison analyzes their business models, recent performance, and market positioning amid evolving healthcare trends like immunology expansion and lung therapy innovations. Traders seeking stability with dividends may eye ABBV, while growth-oriented investors could favor INSM's pipeline catalysts. Understanding relative momentum and risks aids decisions in today's volatile biotech landscape.
ABBV Overview and Recent Performance
AbbVie Inc. (ABBV), a research-based biopharmaceutical giant, focuses on immunology, oncology, neuroscience, aesthetics, and eye care, with key products like Skyrizi, Rinvoq, Imbruvica, and Botox driving revenue over $61 billion annually. In recent market activity, shares traded around $225, reflecting modest YTD performance near flat amid broader sector pressures, with a weekly dip of about 2-3% but monthly gains up to 3%. Sentiment has been bolstered by positive Phase 1 results for obesity candidate ABBV-295 and strong Q4 earnings beats, with adjusted EPS of $2.71 topping estimates, alongside growth in immunology offsetting Humira competition. Analysts project continued upside, with price targets averaging $249 and forward EPS growth of 11-45%.
INSM Overview and Recent Performance
Insmed Incorporated (INSM), a global biopharma firm, targets serious rare diseases, particularly pulmonary conditions, with approved therapies like ARIKAYCE for mycobacterial lung disease and recently launched Brinsupri (brensocatib) for non-CF bronchiectasis. Shares hovered near $140 in recent weeks, with YTD returns mixed around 20% earlier but recent monthly declines of 6-7%, following a 20% drop from a late-2025 mid-stage sinus study failure, partially offset by preliminary 2025 sales beats and 2026 milestones. Brinsupri generated nearly $145 million in its first full quarter, doubling estimates and fueling optimism for peak sales over $3 billion, while pipeline advances in TPIP and INS1201 support sentiment amid revenue growth projections of 139%. Price targets average $211, highlighting biotech momentum despite volatility.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases over 25 top-performing AI trading bots curated from hundreds available, each trading thousands of tickers across diverse strategies like swing trading, trend following, and volatility plays on stocks, ETFs, and crypto. These bots adapt to current market conditions, with standout stats including annualized returns up to +216%, win rates from 53% to 95% (e.g., 94.92% for Biotechnology BIB), and profit factors reaching 25.83. Timeframes range from 5 minutes to 60 days, emphasizing low-drawdown approaches in sectors like biotech and semiconductors. Examples include a biotech bot with +23.91% returns and multi-ticker strategies yielding +132%. Traders can explore these for real-time signals; visit Trending AI Robots to subscribe and copy top performers suited to today's environment.
Head-to-Head Comparison
AbbVie Inc. (ABBV)'s broad business model spans multiple therapies with $61B+ revenue and profitability, contrasting Insmed Incorporated (INSM)'s niche rare lung focus and $606M revenue still scaling toward breakeven. Growth drivers differ: ABBV via immunology successors like Skyrizi amid competition, INSM through Brinsupri ramp-up and pipeline. Recent momentum shows INSM's 86% 1-year edge over ABBV's 6-10%, but ABBV leads in stability (beta 0.33 vs. 1.17). Risks include ABBV's patent pressures and INSM's clinical setbacks/cash burn. Both expose to healthcare, but ABBV offers dividends, while INSM pure growth. Sentiment tilts stable for ABBV, speculative for INSM.
Tickeron AI Verdict
Tickeron’s AI currently favors AbbVie Inc. (ABBV) over Insmed Incorporated (INSM), citing superior trend consistency, low beta for stability, attractive valuation relative to earnings, and reliable catalysts like immunology expansion. While INSM shows stronger historical momentum and launch upside, ABBV's scale and positioning suggest higher probability of near-term outperformance in cautious markets.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and INSM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileINSM’s FA Score has 0 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- INSM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 4 bearish.
- INSM’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а -2.58% price change this week, while INSM (@Biotechnology) price change was -25.80% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.35%. For the same industry, the average monthly price growth was -1.12%, and the average quarterly price growth was +2.63%.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.17%. For the same industry, the average monthly price growth was +5.03%, and the average quarterly price growth was +8.71%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
INSM is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.35% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+0.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | INSM | ABBV / INSM | |
| Capitalization | 358B | 22.5B | 1,591% |
| EBITDA | 17.6B | -1.08B | -1,625% |
| Gain YTD | -9.796 | -40.307 | 24% |
| P/E Ratio | 99.40 | N/A | - |
| Revenue | 61.2B | 820M | 7,463% |
| Total Cash | N/A | 1.22B | - |
| Total Debt | 67.5B | 580M | 11,638% |
ABBV | INSM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 53 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 15 | 63 | |
SMR RATING 1..100 | 1 | 100 | |
PRICE GROWTH RATING 1..100 | 60 | 65 | |
P/E GROWTH RATING 1..100 | 28 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (72) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than INSM’s over the last 12 months.
ABBV's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for INSM (63) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than INSM’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than INSM’s over the last 12 months.
ABBV's Price Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as INSM (65) in the Biotechnology industry. This means that ABBV’s stock grew similarly to INSM’s over the last 12 months.
ABBV's P/E Growth Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for INSM (100) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than INSM’s over the last 12 months.
| ABBV | INSM | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 51% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 62% | 1 day ago 83% |
| MACD ODDS (%) | 1 day ago 66% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 48% | 1 day ago 72% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 78% |
| Advances ODDS (%) | 13 days ago 57% | 13 days ago 71% |
| Declines ODDS (%) | 5 days ago 48% | 5 days ago 72% |
| BollingerBands ODDS (%) | 1 day ago 49% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 44% | 1 day ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NULG | 109.19 | 0.46 | +0.42% |
| Nuveen ESG Large-Cap Growth ETF | |||
| OOSB | 10.47 | N/A | N/A |
| One One S&P 500 and Bitcoin ETF | |||
| CLOB | 50.44 | -0.06 | -0.12% |
| VanEck AA-BB CLO ETF | |||
| NUEM | 42.39 | -0.08 | -0.18% |
| Nuveen ESG Emerging Markets Equity ETF | |||
| DVAL | 14.97 | -0.07 | -0.48% |
| BrandywineGLOBAL Dyn US Lrg Cap Val ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.61% | ||
| PFE - ABBV | 57% Loosely correlated | +0.51% | ||
| BMY - ABBV | 56% Loosely correlated | -0.87% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.64% | ||
| NVS - ABBV | 48% Loosely correlated | -0.55% | ||
| MRK - ABBV | 46% Loosely correlated | -0.09% | ||
More | ||||